Title:
LEBECETIN BEING C-TYPE LECTIN, AS NEOVASCULARIZATION INHIBITOR
Document Type and Number:
Japanese Patent JP2022119955
Kind Code:
A
Abstract:
To provide pharmaceutical compositions for the treatment of retinal neovascularization or choroidal neovascularization disease.SOLUTION: The pharmaceutical composition comprises a protein selected from lebecetin and functional variants thereof, and the protein includes a first subunit containing a specific amino acid sequence and a second subunit containing a further specific amino acid sequence.SELECTED DRAWING: None
Inventors:
XAVIER GUILLONNEAU
FADOUA MONTASSAR
NAZIHA MARRAKCHI
ERIJ MESSADI
FLORIAN SENNLAUB
JOSE-ALAIN SAHEL
FADOUA MONTASSAR
NAZIHA MARRAKCHI
ERIJ MESSADI
FLORIAN SENNLAUB
JOSE-ALAIN SAHEL
Application Number:
JP2022089915A
Publication Date:
August 17, 2022
Filing Date:
June 01, 2022
Export Citation:
Assignee:
SORBONNE UNIV
CENTRE NATIONAL DE LA RECHERCHE SCIENT
INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE
INST PASTEUR DE TUNIS
CENTRE NATIONAL DE LA RECHERCHE SCIENT
INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE
INST PASTEUR DE TUNIS
International Classes:
A61K38/16; A61K35/76; A61K38/17; A61K45/00; A61K48/00; A61P9/00; A61P27/02; A61P43/00; C07K14/46; C12N15/12; C12N15/63
Attorney, Agent or Firm:
Katsumi Iseki
Shuhei Kaneko
Wataru Onishi
Shuhei Kaneko
Wataru Onishi
Previous Patent: game machine
Next Patent: Methods for selective expansion of different T cell subpopulations by altering cell surface signals ...
Next Patent: Methods for selective expansion of different T cell subpopulations by altering cell surface signals ...